Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.19 (market cap $12.58B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.7 (market cap $2.27B). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 5.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, SELLAS Life Sciences Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals.
| HALO | SLS | |
|---|---|---|
Market Cap | $12.58B | $2.27B |
Volume | 2,179,278 | 4,179,659 |
Sector | Health | Health |
52-Week High | $115.22 | $15.46 |
52-Week Low | $61.63 | $1.39 |
Typical Hold Time | 0 Days | — |
Enterprise Value | $14.49B | $2.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
